v3.26.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Consolidated Statements of Operations and Comprehensive Loss      
Revenues $ 20,712,000 $ 28,537,000 $ 33,879,000
Costs of revenues (10,636,000) (17,391,000) (13,827,000)
Gross Profit 10,076,000 11,146,000 20,052,000
Operating (expenses) income:      
Research and development (6,308,000) (8,917,000) (9,861,000)
General and administrative (28,271,000) (23,577,000) (25,387,000)
Selling and marketing (18,343,000) (17,866,000) (16,450,000)
Other operating income   2,000 6,366,000
Gain on disposal of long-lived assets   479,000  
Foreign exchange gain (loss) (2,161,000) (192,000) 200,000
Impairment of intangible assets   (696,000)  
Total operating expenses (55,083,000) (50,767,000) (45,132,000)
Loss from operations (45,007,000) (39,621,000) (25,080,000)
Non-operating (expense) income:      
Interest expense (840,000) (871,000) (15,000)
Interest income 135,000 539,000 629,000
Other income 20,000 188,000 764,000
Change in fair value of investments (179,000) 1,696,000 (581,000)
Impairment loss of long-term investments     (2,009,000)
Loss before income tax benefit and share of net loss in an equity investee (45,871,000) (38,069,000) (26,292,000)
Income tax benefit     81,000
Net loss before share of net loss in an equity investee (45,871,000) (38,069,000) (26,211,000)
Share of net loss in an equity investee (2,187,000) (1,189,000) (48,000)
Net loss (48,058,000) (39,258,000) (26,259,000)
Less:Loss attributable to redeemable noncontrolling interest     (2,602,000)
Accretion to redeemable noncontrolling interest redemption value     3,281,000
Deemed dividends to Wuxi LP     22,000
Net loss attributable to CASI Pharmaceuticals, Inc. $ (48,058,000) $ (39,258,000) $ (26,960,000)
Net loss per share (basic) (in $ per share) $ (2.59) $ (2.56) $ (2.02)
Net loss per share (diluted) (in $ per share) $ (2.59) $ (2.56) $ (2.02)
Weighted average number of ordinary shares outstanding (basic) 18,538,046 15,340,277 13,360,185
Weighted average number of ordinary stock outstanding (diluted) 18,538,046 15,340,277 13,360,185
Comprehensive loss:      
Net loss $ (48,058,000) $ (39,258,000) $ (26,259,000)
Foreign currency translation adjustment (11,000) (574,000) (1,118,000)
Total comprehensive loss (48,069,000) (39,832,000) (27,377,000)
Less: Comprehensive loss attributable to redeemable noncontrolling interest     (3,223,000)
Comprehensive loss attributable to ordinary shareholders $ (48,069,000) $ (39,832,000) $ (24,154,000)